| ZEVRA THERAPEUTICS |
| USA |
| Gesundheit |
| US4884452065 / A2QLX7 |
| 1GDA (Frankfurt) / ZVRA (NASDAQ) |
| FRA:1GDA, ETR:1GDA, 1GDA:GR, NASDAQ:ZVRA |
| - |
| https://zevra.com/ |
|
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on treatments for rare diseases. The company concentrates on rare neurological and sleep-related conditions, including certain urea cycle disorders, Niemann-Pick disease..
>Volltext.. |
| 630.75 Mio. EUR |
| 457.66 Mio. EUR |
| 107.48 Mio. EUR |
| 11.19 Mio. EUR |
| 107.5 Mio. EUR |
| 1.92 EUR |
| 1.01 Mio. EUR |
| 84.02 Mio. EUR |
| 11.22 Mio. EUR |
| 4.27 |
| 182.12% |
| - |
| - |
| - |
| - |
| - |
| ZEVRA |
| 24.07.26 |